Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

BioAscent Discovery Ltd.. (4/12/18). "Press Release: BioAscent Establishes Integrated Drug Discovery Services Offering". Newhouse.

Organisations Organisation BioAscent Discovery Ltd.
  Group BioCity (GB) (Group)
  Organisation 2 University of Dundee, European Screening Centre, Newhouse at BioCity Scotland (European Lead Factory)
  Group University of Dundee
Products Product drug discovery services
  Product 2 chemical compound library (availability)
Persons Person Jones, Phil (BioCity (GB) 201804– CSO at BioAscent before European Screening Centre Biocity Scotland + Roche + MSD)
  Person 2 Smith, Paul (BioCity 201707– CEO of BioAscent Discovery before CXR Biosciences CEO)
     


Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences


BioAscent Discovery Limited (www.bioascent.com) has announced the launch of a comprehensive suite of integrated drug discovery services with immediate effect. Dr Phil Jones will be joining as Chief Scientific Officer to lead BioAscent’s team of expert biologists and chemists, operating from state-of-the-art laboratories at its site in Newhouse, Scotland. With a successful track record in drug discovery from target identification to preclinical and clinical candidate development in all major biological target classes and therapeutic indications, the BioAscent team offers biotech and pharma companies, as well as academic and charitable drug discovery teams, a de-risked approach to drug discovery.

Since 2013, BioAscent has provided scalable and highly secure infrastructure for outsourced compound management, successfully growing its client base over this time. With the integration of an exceptionally experienced team of medicinal chemists and bioscientists into its capabilities, BioAscent is now able to support its clients through each key stage of the drug discovery process. Capabilities include biochemical and biophysical assay development, screening and medicinal chemistry applied to tailored hit discovery approaches including fragment-, focused-, and diversity-based high-throughput screening, hit-to-lead and lead optimisation.

Dr Jones has over 30 years of drug discovery experience, and in senior roles at Roche, Merck Sharpe & Dohme, Schering-Plough and Organon, his teams have been responsible for developing numerous clinical candidates. Prior to BioAscent, Dr Jones established and led the European Screening Centre located at Biocity Scotland. Over the five years of his tenure, this group played a key role in delivering validated hit series to a number of drug companies and academic institutions, working on targets in all major classes, including multiple enzyme types, GPCRs, ion channels, nuclear receptors, protein-protein, protein-RNA & protein-DNA interactions, as well as novel target classes such as splicing factors and chaperones.

“I am excited by BioAscent’s ability to provide a fully flexible and tailored drug discovery solution”, said Dr Jones. “Critically, BioAscent’s extensive drug discovery track record and capabilities cover medicinal and computational chemistry and in vitro biosciences, allowing us to offer a truly integrated service - from initial development of assays, to preclinical candidates. Combined with on-site access to a large, diverse IP-free compound library, this places BioAscent in a near unique position among drug discovery contract research organisations. BioAscent can even provide full compound management capabilities if required, and this exceptional offering was a major factor in my decision to join the company.”

Welcoming Dr Jones’ imminent addition to the BioAscent team, Paul Smith, BioAscent’s CEO, said: “Phil will be joining a company that has shown consistent growth in supporting pharma and biotech companies in both Europe and the US. Now that we have the capability to take targets from initial concept to preclinical candidate, Phil and the BioAscent team will be instrumental in continuing this growth by delivering both stand-alone projects and fully integrated drug discovery services. It’s an exciting time for BioAscent and our clients.”

For more information please visit the BioAscent website at www.bioascent.com.


Editors’ Notes


BioAscent Discovery Ltd.

Founded in 2013, BioAscent is a leading provider of integrated drug discovery services based at the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland. Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management. Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications. As part of its compound management service, BioAscent currently holds and manages over 1 million compounds for our customers, in both liquid and solid formats. Through the Compound Cloud service, the company provides rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Since 2013, the BioAscent team has been responsible for:

>100 biochemical and biophysical assays for drug discovery projects

>50 hit validation/characterisation projects

>30 hit-to-lead campaigns

>80,000 screening plates delivered to our global customers/partners


Product Enquiries

BioAscent Discovery Ltd.
Bo’Ness Road, Newhouse, Lanarkshire, ML1 5UH, UK
t:+44 (0) 1698 534 002
e: mailto:info@bioascent.com
w: www.bioascent.com

Media enquiries

Alto Marketing Limited
David Robinson
t: +44 (0)1489 557672
e: davidr@alto-marketing.com
w: www.alto-marketing.com

   
Record changed: 2018-04-25

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px

More documents for BioCity (GB) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top